These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 2896363)
21. Stimulus effects of N-monoethyl-1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDE) and N-hydroxy-1-(3,4-methylenedioxyphenyl)-2-aminopropane (N-OH MDA) in rats trained to discriminate MDMA from saline. Glennon RA; Misenheimer BR Pharmacol Biochem Behav; 1989 Aug; 33(4):909-12. PubMed ID: 2575759 [TBL] [Abstract][Full Text] [Related]
22. Behavioral suppression following 3,4-methylenenedioxymethamphetamine. Kulmala HK; Boja JW; Schechter MD Life Sci; 1987 Sep; 41(11):1425-9. PubMed ID: 2887995 [TBL] [Abstract][Full Text] [Related]
23. Multiple 5-HT receptors are involved in the effects of acute MDMA treatment: studies on locomotor activity and responding for conditioned reinforcement. Fletcher PJ; Korth KM; Robinson SR; Baker GB Psychopharmacology (Berl); 2002 Jul; 162(3):282-91. PubMed ID: 12122486 [TBL] [Abstract][Full Text] [Related]
24. Effects of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine isomers on central serotonergic, dopaminergic and nigral neurotensin systems of the rat. Johnson M; Letter AA; Merchant K; Hanson GR; Gibb JW J Pharmacol Exp Ther; 1988 Mar; 244(3):977-82. PubMed ID: 2472482 [TBL] [Abstract][Full Text] [Related]
25. Comparison of the behavioral and neurochemical effects of 5,7-DHT, MDMA and D,L-fenfluramine. Lorens SA; Hata N; Cabrera T; Hamilton ME NIDA Res Monogr; 1989; 95():347. PubMed ID: 2577039 [No Abstract] [Full Text] [Related]
26. Inhibition of dopamine release by methylenedioxymethamphetamine is mediated by serotonin. Gazzara RA; Takeda H; Cho AK; Howard SG Eur J Pharmacol; 1989 Sep; 168(2):209-17. PubMed ID: 2575036 [TBL] [Abstract][Full Text] [Related]
27. 3,4-Methylenedioxyethylamphetamine (MDE), a novel analogue of MDMA, produces long-lasting depletion of serotonin in the rat brain. Ricaurte GA; Finnegan KF; Nichols DE; DeLanney LE; Irwin I; Langston JW Eur J Pharmacol; 1987 Jun; 137(2-3):265-8. PubMed ID: 2886355 [TBL] [Abstract][Full Text] [Related]
28. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. O'Hearn E; Battaglia G; De Souza EB; Kuhar MJ; Molliver ME J Neurosci; 1988 Aug; 8(8):2788-803. PubMed ID: 2457659 [TBL] [Abstract][Full Text] [Related]
29. The effects of amphetamine-like designer drugs on monoaminergic systems in rat brain. Gibb JW; Stone DM; Stahl DC; Hanson GR NIDA Res Monogr; 1987; 76():316-21. PubMed ID: 2449619 [TBL] [Abstract][Full Text] [Related]
30. Drug discrimination studies with MDMA and amphetamine. Oberlender R; Nichols DE Psychopharmacology (Berl); 1988; 95(1):71-6. PubMed ID: 2898791 [TBL] [Abstract][Full Text] [Related]
32. Discriminative stimulus properties of (+/-)-3,4-methylenedioxymethamphetamine and (+/-)-3,4-methylenedioxyamphetamine in pigeons. Evans SM; Johanson CE Drug Alcohol Depend; 1986 Oct; 18(2):159-64. PubMed ID: 2877843 [TBL] [Abstract][Full Text] [Related]
33. Elevation of serum prolactin and corticosterone concentrations in the rat after the administration of 3,4-methylenedioxymethamphetamine. Nash JF; Meltzer HY; Gudelsky GA J Pharmacol Exp Ther; 1988 Jun; 245(3):873-9. PubMed ID: 2898523 [TBL] [Abstract][Full Text] [Related]
34. Effects of MDMA, MDA and MDEA on blood pressure, heart rate, locomotor activity and body temperature in the rat involve alpha-adrenoceptors. Bexis S; Docherty JR Br J Pharmacol; 2006 Apr; 147(8):926-34. PubMed ID: 16491100 [TBL] [Abstract][Full Text] [Related]
35. Pharmacological studies of the acute and chronic effects of (+)-3, 4-methylenedioxymethamphetamine on locomotor activity: role of 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B/1D) receptors. McCreary AC; Bankson MG; Cunningham KA J Pharmacol Exp Ther; 1999 Sep; 290(3):965-73. PubMed ID: 10454466 [TBL] [Abstract][Full Text] [Related]
36. Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine. Stone DM; Johnson M; Hanson GR; Gibb JW J Pharmacol Exp Ther; 1988 Oct; 247(1):79-87. PubMed ID: 2902215 [TBL] [Abstract][Full Text] [Related]
37. Differences in the central serotonergic effects of methylenedioxymethamphetamine (MDMA) in mice and rats. Stone DM; Hanson GR; Gibb JW Neuropharmacology; 1987 Nov; 26(11):1657-61. PubMed ID: 2448703 [TBL] [Abstract][Full Text] [Related]
38. The effects of MDMA and other methylenedioxy-substituted phenylalkylamines on the structure of rat locomotor activity. Paulus MP; Geyer MA Neuropsychopharmacology; 1992 Aug; 7(1):15-31. PubMed ID: 1355968 [TBL] [Abstract][Full Text] [Related]
39. Immediate and long-term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat. Stone DM; Merchant KM; Hanson GR; Gibb JW Neuropharmacology; 1987 Dec; 26(12):1677-83. PubMed ID: 2893986 [TBL] [Abstract][Full Text] [Related]
40. Differences in the stimulus properties of 3,4-methylenedioxyamphetamine and 3,4- methylenedioxymethamphetamine in animals trained to discriminate hallucinogens from saline. Callahan PM; Appel JB J Pharmacol Exp Ther; 1988 Sep; 246(3):866-70. PubMed ID: 2901488 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]